Last reviewed · How we verify
NCT04062006
Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica
Phase 2 trial testing Interleukin-2 in Polymyalgia Rheumatica in 15 participants. Status unknown.
31 March 2021
Quick facts
| Lead sponsor | Peking University People's Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 31 August 2019 |
| Primary completion | 31 March 2021 |
| Estimated completion | 30 June 2021 |
Drugs / interventions tested
- Interleukin-2
Conditions studied
- Polymyalgia Rheumatica — all drugs for Polymyalgia Rheumatica →
Sponsor
Peking University People's Hospital
Who can join
50 and older, any sex, with Polymyalgia Rheumatica. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to explore the clinical and immunological efficacy of low-dose Interleukin-2 (IL-2) on polymyalgia rheumatica.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Traditional and Emerging Strategies for Managing Polymyalgia Rheumatica: Insights into New Treatments.
García-Porrúa C, Heras-Recuero E, Blázquez-Sánchez T, Torres-Roselló A, et al · · 2024 · PMID 39518631 · DOI 10.3390/jcm13216492
Verify or expand the search:
- PubMed search for NCT04062006
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Interleukin-2
Trials testing the same drug.
- NCT06677710 — IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis · Phase 1 · suspended
- NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
- NCT06884670 — Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for L · Phase 2 · recruiting
- NCT06598371 — A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 · Phase 1, PHASE2 · recruiting
- NCT06640582 — TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas · Phase 1, PHASE2 · recruiting
Other recruiting trials for Polymyalgia Rheumatica
Currently open trials in the same condition.
- NCT06647134 — A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoi · recruiting
- NCT06331312 — Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) · Phase 3 · active not recruiting
- NCT06172361 — Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica · Phase 3 · recruiting
- NCT05935709 — DANIsh VASculitis Database (DANIVAS) · recruiting
- NCT06460142 — Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic · recruiting
Other Peking University People's Hospital trials
Trials by the same sponsor.
- NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
- NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
- NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
- NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04062006 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
- Last refreshed: 4 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04062006.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing